Acquired Company
GRI Bio, Inc. completed the merger with Vallon Pharmaceuticals, Inc. on April 21, 2023.
Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy. Show more
Start AI Chat
Market Cap
931.3M
52 Wk Range
$N/A - $N/A
Previous Close
$2.49
Open
$2.45
Volume
66,936
Day Range
$2.25 - $2.54
Enterprise Value
0.00
Cash
159.3M
Avg Qtr Burn
N/A
Insider Ownership
23.42%
Institutional Own.
13.28%
Qtr Updated
03/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|